Skip to content

Pharmacopé

Active
Private limited companyfounded 2011active for 15 yearsOude Vaartstraat 9, 2300 Turnhout, BelgiumKBO/BCE: BE 0834.892.064
Summary

Pharmacopé has been active since 2011 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €201,981 and a net result of -€931. Equity has been growing by about 20% per year since 2018. Its solvency ranks better than 94% of 10,818 sector peers (NACE 70, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).

Overview

Official details

Source: KBO
Status
Active since 24-03-2011 Normal situation
Activity
Activities of head offices NACE 70100and 2 others
Establishment unit
2.198.004.360 2300 Turnhout, since 28-03-2011
Financial year end
31 December
Peppol
Reachable since 28-11-2025

Financial position

94 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
< 0.1%
Annual accounts 2025
Gross margin
-€761
Loss
€931
Equity
€201,981
▼ 0.5%
Total assets
€208,146
▲ 0.6%
Turnover not published (abbreviated format)
Score breakdownraises riskLoss of €931 (financial year 2025)lowers riskLiquidity: current ratio 33.60, cash €51,493Sector: Activities of head offices; management consultancy activities (NACE 70)Equity €201,981 (97.0% of total assets)Show the evidence

Checked score

Score 2025
94 / 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 52% of micro companies in head offices and management consultancy (NACE 70)
Financial strength · tick: 2024
Strong
Solvency 100=
equity 97.0% of total assets
Liquidity 81-14
short-term debt 3.0% · cash 24.7%
Profitability 18-57
return on assets -0.4%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.1% (48,528 companies, NACE 70, micro)
Last 24 months 12-2024: < 0.1%lowest value 01-2025: < 0.1%● unchanged vs 12-2024lowest value 02-2025: < 0.1%● unchanged vs 01-2025 03-2025: < 0.1%● unchanged vs 02-2025 04-2025: < 0.1%● unchanged vs 03-2025 05-2025: < 0.1%● unchanged vs 04-2025 06-2025: < 0.1%● unchanged vs 05-2025 07-2025: < 0.1%● unchanged vs 06-2025 08-2025: < 0.1%● unchanged vs 07-2025 09-2025: < 0.1%● unchanged vs 08-2025 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026highest value 08-2026: < 0.1%● unchanged vs 07-2026highest value 09-2026: < 0.1%● unchanged vs 08-2026highest value 10-2026: < 0.1%● unchanged vs 09-2026 11-2026: < 0.1%● unchanged vs 10-2026
Credit of up to €18,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 33.6 (52.07 in 2024), above the usual 1.5. Short-term debt is 3% and cash 24.7% of total assets. 3% of the assets are financed with debt and provisions.
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 70, micro). It does better than 86% of them on solvency, 73% on liquidity, 13% on profitability and 38% on growth.

The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Five signals.
lowers riskraises riskneutral
lowers risk · Liquidity: current ratio 33.60, cash €51,493
NBB · annual accounts
lowers risk · Sector: Activities of head offices; management consultancy activities (NACE 70)
KBO
lowers risk · Equity €201,981 (97.0% of total assets)
NBB · annual accounts
raises risk · Loss of €931 (financial year 2025)
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 23-06-2026, 38 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
38 days early
2024
51 days early
2023
33 days early
2022
17 days early
2021
41 days early
2020
44 days early
2019
29 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 7 accounts on average 36 days before the deadline. In the sector (NACE 70), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 23 June (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven months
Where today falls in the filing period
02-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Key points

  • Positive: Higher solvency than 94% of companies in head offices and management consultancysector median 52.4% · 10,818 companies 97.0% View
  • Positive: Filed on time since financial year 2018accounts within the deadline every year 8 years View

Recent changes

  1. · Gazette deed Change of role: Peeters Jan Maria Bernadette Boudewijn, from manager to director
  2. · Gazette deed Incorporation
All 20 events

Comparable companies

These companies have the same main activity as Pharmacopé: activities of head offices (NACE 70100). They are comparable in size and age: total assets between €149,000 and €257,000, founded between 2009 and 2012.

CompanyTotal assetsGross margin
Pharmacopé Turnhout€208,146-€761
ZEPPELIN INVEST Antwerpen€168,263-€1,260
Planet Group Manage€214,456-€10,602
LIMBURGIA Maaseik€231,923-€9,466
EDGE Kruisem€225,748-€5,895
CAPRI Hooglede€257,366-€43,807
NIFREM Mol€148,854-€10,458
Full comparison

Key facts about Pharmacopé

What is the company number of Pharmacopé?
The company number of Pharmacopé is 0834.892.064. The VAT number is the same number with BE in front: BE 0834.892.064.
Where is Pharmacopé based?
The registered office is at Oude Vaartstraat 9, 2300 Turnhout.Company details
What does Pharmacopé do?
According to the KBO register, the main activity is activities of head offices (NACE 70100).
What is the legal form of Pharmacopé?
The legal form of Pharmacopé is Private limited company (BV).
When was Pharmacopé founded?
Pharmacopé was founded on 24-03-2011.
Is Pharmacopé still active?
Yes, Pharmacopé is an active enterprise in the KBO register.
What is the turnover of Pharmacopé?
The annual accounts for financial year 2025 state no turnover. The abbreviated format does not require it.Financials
Is Pharmacopé profitable?
In financial year 2025, Pharmacopé made a loss of €931.
Where can I find the annual accounts of Pharmacopé?
Pharmacopé filed 14 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Pharmacopé due?
Pharmacopé must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.